|
Kasimova A.R., Kolbin A.S.
Pharmacoeconomic analysis of apixaban use for secondary thromboprophylaxis at outpatient stage among oncological patients
|
№1 / 2024
|
|
Prekina V.I., Kunyaeva T.A., Shokina S.V., Samolvina O.G., Skopina Yu.A.
Correction of risk factors in patients with atrial fibrillation
|
№8 / 2023
|
|
Tarzimanova A.I.
Impact of long-term antiarrhythmic therapy on the progression of atrial fibrillation from paroxysmal to permanent form
|
№7 / 2023
|
|
Vorobyeva N.M., Malaya I.P., Alimova E.R., Tkacheva O.N.
Prevention of gastrointestinal bleeding in patients with atrial fibrillation receiving oral anticoagulants: Whom? When? How?
|
№5 / 2023
|
|
Adasheva T.V., Samorukova E.I., Gubernatorova E.E., Lobanova E.G., Shahrai N.B.
Anticoagulant therapy for non-valvular atrial fibrillation patients with CHA2DS2-VASC score 1 (regardless of gender): A personalized approach based on risk/benefit analysis
|
№4 / 2023
|
|
Kuznetsova M.V., Tarasov A.V., Vinuesa D.I., Sambrano V.S., Davtyan K.V., Drapkina O.M.
Atrial fibrillation in patients with left ventricular hypertrophy: which tactics is optimal for rhythm control strategy?
|
№9 / 2022
|
|
Kokorin V.A., Boeva O.I.
Prevention of stroke and systemic embolism in patients with atrial fibrillation: focus on apixaban
|
№9 / 2022
|
|
Doshchitsin V.L., Syrov A.V.
Propafenone and sotalol use in the treatment of atrial fibrillation
|
№8 / 2022
|
|
Ruyatkina L.A., Ruyatkin D.S.
Hyperthyroidism and atrial fibrillation: a tangle of interdisciplinary problems associated with COVID-19 pandemic
|
№8 / 2022
|
|
Tarzimanova A.I.
Obesity and atrial fibrillation: mechanisms of occurence and current treatment guidelines
|
№7 / 2022
|
|
Tarzimanova A.I.
The significance of non-alcoholic fatty liver disease in atrial fibrillation development: view of cardiologist
|
№5 / 2022
|
|
Alieva A.M., Reznik E.V., Teplova N.V., Totolyan G.G., Gasanova E.T., Kalova M.R., Sabanchieva E.E., Nikitin I.G.
JDP2 – a new promising biological marker in cardiovascular pathology
|
№5 / 2022
|
Русский
